BDBM50301021 (+)-dihydrotetrabenzaine::CHEMBL576222::US11053242, Compound R,R,R-DHTBZ

SMILES COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC

InChI Key InChIKey=WEQLWGNDNRARGE-DJIMGWMZSA-N

Data  13 KI  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 50301021   

TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  1.03nMAssay Description:Displacement of [125I]-iodovinyl-TBZ from VMAT2 in rat striatal homogenate after 60 mins by gamma countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  1.90nMAssay Description:Examples of techniques for determining the capability of a compound to inhibit VMAT2 are provided below. The procedure is adapted from that described...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  1.90nMAssay Description:Examples of techniques for determining the capability of a compound to inhibit VMAT2 are provided below. The procedure is adapted from that described...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  1.90nMAssay Description:Examples of techniques for determining the capability of a compound to inhibit VMAT2 are provided below. The procedure is adapted from that described...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  2nMAssay Description:Inhibition of VMAT2 in rat brainMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  2nMAssay Description:Inhibition of VMAT2 in rat brainMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  2.45nMAssay Description:Displacement of [125I]-iodovinyl-TBZ from VMAT2 in rat striatal membrane homogenatesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Homo sapiens (Human))
Neurocrine Biosciences

US Patent
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  2.60nMAssay Description:Examples of techniques for determining the capability of a compound to inhibit VMAT2 are provided below. The procedure is adapted from that described...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSynaptic vesicular amine transporter(Homo sapiens (Human))
Neurocrine Biosciences

US Patent
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  2.60nMAssay Description:Examples of techniques for determining the capability of a compound to inhibit VMAT2 are provided below. The procedure is adapted from that described...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSynaptic vesicular amine transporter(Homo sapiens (Human))
Neurocrine Biosciences

US Patent
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  2.60nMAssay Description:Examples of techniques for determining the capability of a compound to inhibit VMAT2 are provided below. The procedure is adapted from that described...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  3.75nMAssay Description:Displacement of [3H]-DTBZ from VMAT2 in rat striatal membrane homogenatesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  3.96nMAssay Description:Displacement of [3H]DHTBZ from Sprague-Dawley rat striatum VMAT2 after 1 hr by liquid scintillation countingMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataKi:  4.20nMAssay Description:Inhibition of [3H]-DHTBZ binding to VMAT2 from rat forebrain membranesMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50:  20nMAssay Description:Inhibition of [3H]DA uptake at VMAT2 in rat striatal synaptosome incubated for 10 mins followed by [3H]DA addition and measured after 20 mins by TopC...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Yantai University

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Yantai University

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2D6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Yantai University

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSynaptic vesicular amine transporter(Rattus norvegicus (Rat))
University Of Pennsylvania

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50:  15nMAssay Description:Inhibition of [3H]DTBZ binding to VMAT2 in rat brain incubated for 30 mins by liquid scintillation spectrometry analysisMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2B6(Homo sapiens (Human))
Yantai University

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP2B6 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 3A4(Homo sapiens (Human))
Yantai University

Curated by ChEMBL
LigandPNGBDBM50301021((+)-dihydrotetrabenzaine | CHEMBL576222 | US110532...)
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of CYP3A4 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed